$GRTSQ
Gritstone bio, Inc.

2019 Q4 Form 10-K Financial Statement

#000156459020009886 Filed on March 11, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q2 2018 Q4
Revenue $884.0K $1.150M $1.091M
YoY Change -18.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.620M $4.840M $3.870M
YoY Change 45.22% 72.24% 111.48%
% of Gross Profit
Research & Development $23.58M $18.53M $15.25M
YoY Change 54.62% 46.02% -3.17%
% of Gross Profit
Depreciation & Amortization $1.450M $1.090M $1.070M
YoY Change 35.51% 12.37% 64.62%
% of Gross Profit
Operating Expenses $29.20M $23.36M $19.12M
YoY Change 52.72% 50.71% 8.76%
Operating Profit -$28.31M -$22.21M -$18.03M
YoY Change 57.06% 43.28% 2.54%
Interest Expense $610.0K $1.042M $690.0K
YoY Change -11.59% 3261.29% 228.57%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$27.70M -$21.17M -$17.34M
YoY Change 59.75% 36.85% -0.17%
Income Tax
% Of Pretax Income
Net Earnings -$27.70M -$21.17M -$17.34M
YoY Change 59.79% 36.83% -0.17%
Net Earnings / Revenue -3133.94% -1841.04% -1589.18%
Basic Earnings Per Share
Diluted Earnings Per Share -$770.9K -$630.4K -$584.6K
COMMON SHARES
Basic Shares Outstanding 35.72M 29.04M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q2 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.8M $181.2M $153.1M
YoY Change -16.53% 180.93%
Cash & Equivalents $57.40M $107.7M $52.18M
Short-Term Investments $70.40M $73.50M $100.9M
Other Short-Term Assets $772.0K $389.0K $449.0K
YoY Change 71.94% -83.79% 372.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $131.3M $184.7M $157.6M
YoY Change -16.72% 176.08% 78.16%
LONG-TERM ASSETS
Property, Plant & Equipment $26.91M $18.97M $29.49M
YoY Change -8.76% -31.03% 8.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $500.0K
YoY Change
Other Assets $2.800M $100.0K $250.0K
YoY Change 1020.0% -93.33% 0.0%
Total Long-Term Assets $53.12M $43.48M $31.92M
YoY Change 66.39% 49.43% 10.76%
TOTAL ASSETS
Total Short-Term Assets $131.3M $184.7M $157.6M
Total Long-Term Assets $53.12M $43.48M $31.92M
Total Assets $184.4M $228.2M $189.6M
YoY Change -2.73% 137.69% 61.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.621M $5.253M $4.825M
YoY Change -4.23% 94.56% 22.62%
Accrued Expenses $1.041M $1.803M $740.0K
YoY Change 40.68% -27.88% -50.34%
Deferred Revenue $4.956M $5.498M $5.340M
YoY Change -7.19%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.50M $18.07M $15.11M
YoY Change 29.07% 247.4% 97.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $10.50M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $27.70M $12.00K
YoY Change -100.0% 1631.25% -87.5%
Total Long-Term Liabilities $0.00 $27.70M $12.00K
YoY Change -100.0% 128.93% -87.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.50M $18.07M $15.11M
Total Long-Term Liabilities $0.00 $27.70M $12.00K
Total Liabilities $50.05M $45.80M $40.44M
YoY Change 23.76% 164.75% 102.0%
SHAREHOLDERS EQUITY
Retained Earnings -$221.0M -$165.7M -$126.4M
YoY Change 74.84% 105.11%
Common Stock $17.00K $17.00K $16.00K
YoY Change 6.25% 1500.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $134.3M $182.4M $149.1M
YoY Change
Total Liabilities & Shareholders Equity $184.4M $228.2M $189.6M
YoY Change -2.73% 137.69% 61.6%

Cashflow Statement

Concept 2019 Q4 2019 Q2 2018 Q4
OPERATING ACTIVITIES
Net Income -$27.70M -$21.17M -$17.34M
YoY Change 59.79% 36.83% -0.17%
Depreciation, Depletion And Amortization $1.450M $1.090M $1.070M
YoY Change 35.51% 12.37% 64.62%
Cash From Operating Activities -$22.45M -$18.41M -$12.99M
YoY Change 72.83% 53.29% -9.41%
INVESTING ACTIVITIES
Capital Expenditures -$5.590M -$2.250M -$2.280M
YoY Change 145.18% 92.31% -34.86%
Acquisitions
YoY Change
Other Investing Activities -$35.76M $24.03M -$89.17M
YoY Change -59.9% 88.47% 100.7%
Cash From Investing Activities -$41.35M $21.78M -$91.46M
YoY Change -54.79% 88.08% 90.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $69.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.270M 69.79M 90.70M
YoY Change -95.29% 748.0% 2699.38%
NET CHANGE
Cash From Operating Activities -22.45M -18.41M -12.99M
Cash From Investing Activities -41.35M 21.78M -91.46M
Cash From Financing Activities 4.270M 69.79M 90.70M
Net Change In Cash -59.53M 73.16M -13.75M
YoY Change 332.95% 837.95% -76.71%
FREE CASH FLOW
Cash From Operating Activities -$22.45M -$18.41M -$12.99M
Capital Expenditures -$5.590M -$2.250M -$2.280M
Free Cash Flow -$16.86M -$16.16M -$10.71M
YoY Change 57.42% 49.08% -1.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Registrant Name
EntityRegistrantName
Gritstone Oncology, Inc.
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001656634
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36976352
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
277100000
CY2019 dei Entity File Number
EntityFileNumber
001-38663
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4859534
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
5959 Horton Street
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
CY2019 dei City Area Code
CityAreaCode
510
CY2019 dei Local Phone Number
LocalPhoneNumber
871-6100
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57408000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
70368000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3497000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
131273000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26911000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23427000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1353000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2018Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
10490000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20985000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9560000
CY2019Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2778000
CY2019Q4 us-gaap Assets
Assets
184389000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4621000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4598000
CY2019Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1779000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1041000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2505000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4956000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19500000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4365000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1187000
CY2019 dei Trading Symbol
TradingSymbol
GRTS
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52183000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
100927000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4526000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
157636000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29494000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2018Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2428000
CY2018Q4 us-gaap Assets
Assets
189558000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4825000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3951000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
740000
CY2018Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
252000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5340000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15108000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2017 us-gaap Operating Expenses
OperatingExpenses
41763000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-41763000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82896000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19409000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11806000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59103000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
41689000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54965000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6072000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.26
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-20.70
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64786000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8919281
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1999044
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35691000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13473000
CY2019Q4 us-gaap Liabilities
Liabilities
50045000
CY2018Q4 us-gaap Liabilities
Liabilities
40436000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
355291000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
275593000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220988000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126402000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
134344000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
149122000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
184389000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189558000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36332956
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28823130
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36332956
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28823130
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018 us-gaap Operating Expenses
OperatingExpenses
66771000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
109000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-94324000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.81
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33554823
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
95798000
CY2017 grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
117000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1126000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
97282000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20935000
CY2018 grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
97000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2018 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
36000
CY2018 grts Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
13000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2959000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
413000
CY2019 grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
63000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
452000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5299000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4745000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3961000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1970000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1349000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
552000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
158000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
5299000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2995000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1126000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
6382000
CY2018 us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2017 us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-37000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1781000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
416000
CY2019 grts Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
3328000
CY2018 grts Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
0
CY2017 grts Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
0
CY2019 grts Increase Decrease In Deposit And Other Assets Current
IncreaseDecreaseInDepositAndOtherAssetsCurrent
351000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2273000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1724000
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1190000
CY2019 grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
9000
CY2018 grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
-582000
CY2019 grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1526000
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-396000
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-311000
CY2019 grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
54000
CY2018 grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
0
CY2017 grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
0
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4297000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18813000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85011000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38162000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34971000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
102160000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
63228000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
112993000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48720000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
41467000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11522000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
80979000
CY2017 grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
0
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16173000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5663000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39999000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
31000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15841000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33252000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75202000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92586000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14000
CY2019 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
807000
CY2018 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
3080000
CY2017 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
20935000
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
95798000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74395000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
110441000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95812000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5225000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13176000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27589000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53175000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12410000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58400000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1232000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1482000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
900000
CY2019 grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
1878000
CY2018 grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
0
CY2019 grts Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
0
CY2018 grts Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
0
CY2017 grts Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
9300000
CY2019 grts Receivable From Lessor Funded Financing
ReceivableFromLessorFundedFinancing
0
CY2018 grts Receivable From Lessor Funded Financing
ReceivableFromLessorFundedFinancing
0
CY2017 grts Receivable From Lessor Funded Financing
ReceivableFromLessorFundedFinancing
1226000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to preclinical and clinical study trial accruals, fair value of assets and liabilities, the fair value of right-of-use assets (&#8220;ROU Assets&#8221;) and lease liabilities, revenue recognition, and the fair value of stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. Through December&#160;31, 2019, the Company has no off-balance sheet concentrations of credit risk.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to those of other clinical-stage immunotherapy companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services.</p>
CY2019Q4 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
116750000
CY2018Q4 grts Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
149207000
CY2018Q4 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
86000
CY2018Q4 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
149122000
CY2019Q4 grts Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
127800000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
992000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
992000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
58400000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53175000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q4 grts Capital Expenditure Due But Not Yet Received
CapitalExpenditureDueButNotYetReceived
1200000
CY2019 grts Percentage Of Amount Realized Upon Ultimate Settlement
PercentageOfAmountRealizedUponUltimateSettlement
0.50
CY2019Q4 grts Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
116726000
CY2019Q4 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2018Q4 grts Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
153100000
CY2019 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2019Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0
CY2019 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2018 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2017 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37221000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36245000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10310000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6751000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
271000
CY2019 us-gaap Lease Cost
LeaseCost
6653000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
2495000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12331000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y2M12D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5366000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6359000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3742000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3459000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3449000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12530000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
34905000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9827000
CY2019Q4 grts Operating Lease Tenant Improvement Allowance
OperatingLeaseTenantImprovementAllowance
1588000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
23490000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
6700000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
CY2017 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
18813000
CY2019 grts Contract With Customer Liability Addition
ContractWithCustomerLiabilityAddition
0
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-4297000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14516000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1252000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
966000
CY2019Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
482000
CY2018Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
462000
CY2019Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
1473000
CY2018Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
1789000
CY2018Q4 us-gaap Prepaid Rent
PrepaidRent
860000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
290000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
449000
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
1201000
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
632000
CY2019Q4 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
585000
CY2018Q4 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
554000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
992000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
992000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
445000
CY2019Q4 grts Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
761000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
280000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
295000
CY2019 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote per share.
CY2019Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69700000
CY2019Q4 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000
CY2019Q4 grts Percentage Of Proceeds Payable As Compensation To Underwriter
PercentageOfProceedsPayableAsCompensationToUnderwriter
0.030
CY2019Q4 grts Maximum Offering Expenses Agreed To Be Reimbursed
MaximumOfferingExpensesAgreedToBeReimbursed
50000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.020
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.830
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.880
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.940
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.08
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.59
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.00
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2695110
CY2019 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsAuthorized
1160000
CY2019 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
1312610
CY2019 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised
0
CY2019 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
295484
CY2019 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Repurchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRepurchased
13899
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2851883
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2429859
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1312610
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
281024
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
295484
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3165961
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1124222
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2939089
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.31
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.30
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.61
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.46
CY2019 grts Share Based Compensation Arrangements By Share Based Payment Award Options Repurchased In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
0.35
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.83
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.16
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.54
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M9D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M12D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y10M17D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M17D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25646000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8875000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5433000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8864000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2970000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
750000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
80000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11500000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M3D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5000000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5299000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2995000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1126000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.022
CY2019 grts Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
-0.008
CY2018 grts Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
-0.010
CY2017 grts Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
-0.023
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.173
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.026
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.044
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.041
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.263
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.285
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.207
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017 grts Deduction For Net Operating Losses Percentage
DeductionForNetOperatingLossesPercentage
0.80
CY2017 grts Reduction To Deferred Tax Assets
ReductionToDeferredTaxAssets
7100000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24900000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18400000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45228000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27311000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6205000
CY2019Q4 grts Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
5920000
CY2018Q4 grts Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
0
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2172000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1387000
CY2019Q4 grts Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
2700000
CY2018Q4 grts Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1726000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3659000
CY2019 grts Ownership Interest Rate Change Over Period
OwnershipInterestRateChangeOverPeriod
P3Y
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4503000
CY2019Q4 grts Deferred Tax Assets Lease Financing Obligation
DeferredTaxAssetsLeaseFinancingObligation
0
CY2018Q4 grts Deferred Tax Assets Lease Financing Obligation
DeferredTaxAssetsLeaseFinancingObligation
2658000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
0
CY2019Q4 grts Deferred Tax Liabilities Other Depreciation
DeferredTaxLiabilitiesOtherDepreciation
638000
CY2018Q4 grts Deferred Tax Liabilities Other Depreciation
DeferredTaxLiabilitiesOtherDepreciation
655000
CY2019Q4 grts Deferred Tax Liabilities Leased Building Depreciation
DeferredTaxLiabilitiesLeasedBuildingDepreciation
0
CY2018Q4 grts Deferred Tax Liabilities Leased Building Depreciation
DeferredTaxLiabilitiesLeasedBuildingDepreciation
2446000
CY2019Q4 grts Deferred Tax Liabilities Operating Lease Right Of Uset Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets
5904000
CY2018Q4 grts Deferred Tax Liabilities Operating Lease Right Of Uset Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets
0
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59342000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34484000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59342000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
34484000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2077000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1089000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
230000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
711000
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
453000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
47000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1244000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1441000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
906000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2610000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3209915
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2656826
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19728915
CY2019Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
884000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
984000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1150000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1347000
CY2019Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-28313000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28484000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22214000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18929000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-27704000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-27548000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21172000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-18009000
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1091000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96000
CY2018Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-18027000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18614000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15504000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13439000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-17338000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-18588000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-15473000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-13376000
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.60
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.57
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.03

Files In Submission

Name View Source Status
0001564590-20-009886-index-headers.html Edgar Link pending
0001564590-20-009886-index.html Edgar Link pending
0001564590-20-009886.txt Edgar Link pending
0001564590-20-009886-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcw4iysyswwa000001.jpg Edgar Link pending
gcw4iysyswwa000002.jpg Edgar Link pending
gcw4iysyswwa000003.jpg Edgar Link pending
gcw4iysyswwa000004.jpg Edgar Link pending
gcw4iysyswwa000005.jpg Edgar Link pending
gcw4iysyswwa000006.jpg Edgar Link pending
gcw4iysyswwa000007.jpg Edgar Link pending
gcw4iysyswwa000008.jpg Edgar Link pending
gcw4iysyswwa000009.jpg Edgar Link pending
gcw4iysyswwa000010.jpg Edgar Link pending
gcw4iysyswwa000011.jpg Edgar Link pending
gcw4iysyswwa000012.jpg Edgar Link pending
gcw4iysyswwa000013.jpg Edgar Link pending
gcw4iysyswwa000014.jpg Edgar Link pending
gcw4iysyswwa000015.jpg Edgar Link pending
gcw4iysyswwa000016.jpg Edgar Link pending
gcw4iysyswwa000017.jpg Edgar Link pending
gcw4iysyswwa000018.jpg Edgar Link pending
gcw4iysyswwa000019.jpg Edgar Link pending
gcw4iysyswwa000020.jpg Edgar Link pending
gcw4iysyswwa000021.jpg Edgar Link pending
gcw4iysyswwa000022.jpg Edgar Link pending
gcw4iysyswwa000023.jpg Edgar Link pending
gcw4iysyswwa000024.jpg Edgar Link pending
gcw4iysyswwa000025.jpg Edgar Link pending
gcw4iysyswwa000026.jpg Edgar Link pending
gcw4iysyswwa000027.jpg Edgar Link pending
gcw4iysyswwa000028.jpg Edgar Link pending
grts-10k_20191231.htm Edgar Link pending
grts-20191231.xml Edgar Link completed
grts-20191231.xsd Edgar Link pending
grts-20191231_cal.xml Edgar Link unprocessable
grts-20191231_def.xml Edgar Link unprocessable
grts-20191231_lab.xml Edgar Link unprocessable
grts-20191231_pre.xml Edgar Link unprocessable
grts-ex231_6.htm Edgar Link pending
grts-ex311_10.htm Edgar Link pending
grts-ex312_7.htm Edgar Link pending
grts-ex321_9.htm Edgar Link pending
grts-ex43_310.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending